NCT00703651View on ClinicalTrials.gov

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

1,150

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

May 31, 2006

Study Completion Date

July 31, 2006

Conditions

InfluenzaOrthomyxoviridae InfectionMyxovirus Infection

Interventions

BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.1 mL, ID. 1 injection/year for 3 years

BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.1 mL, ID. 1 injection/year for 3 years.

BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.5 mL, IM. 1 injection/year for 3 years

Trial Locations (8)

Unknown

Gribomont

Kraainem

Linkebeek

Molenbeek

Thuin

Hradec Králové

Kaunas

Vilnius

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00703651 - Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults | Biotech Hunter | Biotech Hunter